color growth segment
updat growth segment punch line cah numbers/com
today see pharma distribut segment ebit declin vs
prior assumpt expect medic segment ebit grow vs
previous howev partial off-set higher level corpor
expens explain increas ep estim
despit beat
call provid addit color regard segment out-performance
follow sizabl amount corpor expens delay
expect realiz futur quarter although exact size
expens provid manag note compani invest
yet tie segment would flow line revers ny
opioid assess increas brand volum growth specialti posit
benefit distributor decemb quarter improv certain product
area medic busi benefit tie cost save initi
manag indic expect exceed target mln cost save
exceed target mln save compani tsa
roll-off manag indic complet final major tsa roll-off
relat patient recoveri busi acquir januari
compani remain track achiev accret goal acquisit
rais estim out-performance segment even though today result
better-than-expect vs prior guidanc segment still wit ebit
declin quit wood yet key variabl consist
ebit growth overal gener drug price still wait
improv oral solid gener price deflat particular cah cost control
encourag meantim asid also bump ep
estim maintain ew rate rais pt base
price-to-earnings slightli higher ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
equal weight equal weight
compani continu go transit relat
medic busi core drug
distribut busin continu lap headwind
upsid case see gener price improv
brand inflat come slightli exoecatuib
lead multipl expans
downsid case see gener price continu
remain heavili deflationari slower expect
improv seen cordi busi lead
lower price multipl contract
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
singl digit growthlow singl digit growthmid singl digit growthnon-gaap effect tax expens milnon-gaap dilut milcapit milpharma segmentrevenu growthlow singl digit growthlow singl digit growthmid high singl digit growthprofit ebit growthhigh singl low doubl digit declinehigh singl low doubl digit declinehigh singl low doubl digit declinegener pricingsimilar pricingmid-singl digitmid-singl digitmid-singl digitmed segmentrev growthlow singl digit growthlow singl digit growthapproxim flatebit growthmid high singl digit growthmid high singl digit growthmid high singl digit growth barclay cardin
 quarterli revenu model mil cahcahcahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahcahcahcahcahoper profit ebit ebit ebit ebit barclay
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
 annual revenu model mil cahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin annual oper profit mil cahcahcahoper profit ebit ebit ebit ebit barclay
 annual incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
